The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
Open accessAbstract
Antibody-drug conjugates (ADCs) allow selective targeting of cytotoxic drugs to cancer cells presenting tumor-associated surface markers, thereby minimizing systemic toxicity. Traditionally, the drug is conjugated nonselectively to cysteine or lysine residues in the antibody. However, these strategies often lead to heterogeneous products, which make optimization of the biological, physical, and pharmacological properties of an ADC challenging. Here we demonstrate the use of genetically encoded unnatural amino acids with orthogonal chemical reactivity to synthesize homogeneous ADCs with precise control of conjugation site and stoichiometry. p -Acetylphenylalanine was site-specifically incorporated into an anti-Her2 antibody Fab fragment and full-length IgG in Escherichia coli and mammalian cells, respectively. The mutant protein was selectively and efficiently conjugated to an auristatin derivative through a stable oxime linkage. The resulting conjugates demonstrated excellent pharmacokinetics, potent in vitro cytotoxic activity against Her2 + cancer cells, and complete tumor regression in rodent xenograft treatment models. The synthesis and characterization of homogeneous ADCs with medicinal chemistry-like control over macromolecular structure should facilitate the optimization of ADCs for a host of therapeutic uses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Expanding the Genetic Code of Escherichia coli
Wang, L., Brock, A., Herberich, B., & Schultz, P. G. (2001) · Science · doi:10.1126/science.1060077 · Cited by 1,499
Self-citationSite-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Self-citationEffects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Shen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S.-F., Mai, E., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2108 · Cited by 1,008
Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
An Enhanced System for Unnatural Amino Acid Mutagenesis in E. coli
Young, T. S., Ahmad, I., Yin, J. A., & Schultz, P. G. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.10.030 · Cited by 637
Self-citationKrop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J.-H., Sliwkowski, M. X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2071 · Cited by 595
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0502917 · Cited by 515
Nucleophilic Catalysis of Oxime Ligation
Dirksen, A., Hackeng, T. M., & Dawson, P. E. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200602877 · Cited by 488
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., Senter, P. D., & Alley, S. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2069 · Cited by 393
Genetic incorporation of unnatural amino acids into proteins in mammalian cells
Liu, W., Brock, A., Chen, S., Chen, S., & Schultz, P. G. (2007) · Nature Methods · doi:10.1038/nmeth1016 · Cited by 373
Self-citationDiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K., Dougher, M. M., Sridharan, L., Kunz, A., Hamann, P. R., Gorovits, B., Udata, C., et al. (2004) · Blood · doi:10.1182/blood-2003-07-2466 · Cited by 361
Addition of the keto functional group to the genetic code of Escherichia coli
Wang, L., Zhang, Z., Brock, A., & Schultz, P. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0234824100 · Cited by 356
Self-citationJunutula, J. R., Flagella, K. M., Graham, R. A., Parsons, K. L., Ha, E., Raab, H., Bhakta, S., Nguyen, T., Dugger, D. L., Li, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0987 · Cited by 292
Cell killing by antibody–drug conjugates
Kovtun, Y. V., & Goldmacher, V. S. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.04.010 · Cited by 246
Gross, S., & Piwnica-Worms, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.12.011 · Cited by 229
MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?
Chambers, A. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1528 · Cited by 218
Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates
Zhao, R. Y., Wilhelm, S. D., Audette, C., Jones, G., Leece, B. A., Lazar, A. C., Goldmacher, V. S., Singh, R., Kovtun, Y., Widdison, W. C., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2002958 · Cited by 215
Drug-conjugated monoclonal antibodies for the treatment of cancer
LAMBERT, J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.017 · Cited by 210
Boswell, C. A., Mundo, E. E., Zhang, C., Bumbaca, D., Valle, N. R., Kozak, K. R., Fourie, A., Chuh, J., Koppada, N., Saad, O., et al. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200212a · Cited by 207
Tolcher, A. W., Ochoa, L., Hammond, L. A., Patnaik, A., Edwards, T., Takimoto, C., Smith, L., de Bono, J., Schwartz, G., Mays, T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.137 · Cited by 206
CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
Tse, K. F., Jeffers, M., Pollack, V. A., McCabe, D. A., Shadish, M. L., Khramtsov, N. V., Hackett, C. S., Shenoy, S. G., Kuang, B., Boldog, F. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2018 · Cited by 183
Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate
Doronina, S. O., Bovee, T. D., Meyer, D. W., Miyamoto, J. B., Anderson, M. E., Morris-Tilden, C. A., & Senter, P. D. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800289a · Cited by 179
Bioluminescent imaging: a critical tool in pre‐clinical oncology research
O'Neill, K., Lyons, S. K., Gallagher, W. M., Curran, K. M., & Byrne, A. T. (2010) · The Journal of Pathology · doi:10.1002/path.2656 · Cited by 174
Klerk, C. P. W., Overmeer, R. M., Niers, T. M. H., Versteeg, H. H., Richel, D. J., Buckle, T., Noorden, C. J. F. V., & van Tellingen, O. (2007) · BioTechniques · doi:10.2144/000112515 · Cited by 164
Site-specific DNA-antibody conjugates for specific and sensitive immuno-PCR
Kazane, S. A., Sok, D., Cho, E. H., Uson, M. L., Kühn, P., Schultz, P. G., & Smider, V. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120682109 · Cited by 155
Self-citationThe Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
Alley, S. C., Zhang, X., Okeley, N. M., Anderson, M. E., Law, C., Senter, P. D., & Benjamin, D. R. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.155549 · Cited by 136
The next generation of antibody-drug conjugates comes of age.
Beck, A., Haeuw, J., Wurch, T., Goetsch, L., Bailly, C., & Corvaı̈a, N. (2010) · PubMed · Cited by 120
Oflazoglu, E., Stone, I. J., Gordon, K. A., Wood, C. G., Repasky, E. A., Grewal, I. S., Law, C., & Gerber, H. P. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0916 · Cited by 114
Arming antibodies for cancer therapy
Polakis, P. G. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.008 · Cited by 81
Hutchins, B. M., Kazane, S. A., Staflin, K., Forsyth, J. S., Felding‐Habermann, B., Schultz, P. G., & Smider, V. V. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.01.011 · Cited by 75
Self-citationSelective Formation of Covalent Protein Heterodimers with an Unnatural Amino Acid
Hutchins, B. M., Kazane, S. A., Staflin, K., Forsyth, J. S., Felding‐Habermann, B., Smider, V. V., & Schultz, P. G. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.01.006 · Cited by 57
Self-citationComment Re: MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?
Hollestelle, A., & Schutte, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2396 · Cited by 38
Goff, L. W., Papadopoulos, K. P., Posey, J. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.e15625 · Cited by 18
Staflin, K., Krueger, J. S., Hachmann, J., Forsyth, J. S., Lorger, M., Steiniger, S. C. J., Mee, J. M., Pop, C., Salvesen, G. S., Janda, K. D., et al. (2010) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9320-5 · Cited by 15
Self-citationAntibody–Cytotoxic Compound Conjugates for Oncology
Vater, C. A., & Goldmacher, V. S. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0507-9_9 · Cited by 11
Cited by
Inverse electron demand Diels–Alder reactions in chemical biology
Oliveira, B. L., Guo, Z., & Bernardes, G. J. L. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00184c · Cited by 1,139
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Tsuchikama, K., & An, Z. (2018) · Protein & Cell · doi:10.1007/s13238-016-0323-0 · Cited by 786
Site-specific antibody drug conjugates for cancer therapy
Panowski, S., Bhakta, S., Raab, H., Polakis, P., & Junutula, J. R. (2014) · mAbs · doi:10.4161/mabs.27022 · Cited by 676
Exploring the next generation of antibody–drug conjugates
Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00850-2 · Cited by 659
Metadata
- Authors
- Axup, J. Y., Bajjuri, K. M., Ritland, M., Hutchins, B. M., Kim, C. H., Kazane, S. A., Halder, R., Forsyth, J. S., Santidrian, A. F., Stafin, K., Lu, Y., Tran, H., Seller, A. J., Biroc, S. L., Szydlik, A., Pinkstaff, J. K., Tian, F., Sinha, S. C., Felding-Habermann, B., Smider, V. V., & Schultz, P. G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-09-17
- Volume
- 109
- Issue
- 40
- Pages
- 16101-16106
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2126183505
- Cited by
- 596
- References
- 41
- FWCI
- 34.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.